|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer显示文摘AIM: To identify suitable biomarkers of response to bevacizumab(BV)- it remains an open question. The measurement of serum vascular endothelial growth factor(VEGF) has been proposed as a predictive factor for this drug, even if literature data are contradictory. METHODS: We prospectively evaluated the role of BV, total and not BV-bound VEGF and angiopoietin-2(Ang-2) serum levels as potential predictive factors of response for BV in combination with an oxaliplatinbased chemotherapy. BV, Ang-2, total and not BVbound VEGF levels were measured at baseline, before 2^(nd) and 5^(th) cycle of oxaliplatin-based chemotherapy in 20 consecutive metastatic colorectal cancer patients. RESULTS: Results were correlated to response to treatment. Variability in BV levels have been found, with decreased level in less responding patients. In particular, the concentration of BV increased of 3.96 ± 0.69 folds in serum of responsive patients after 3 more cycles of therapy compared to those with stable or progressive disease with a 0.72 ± 0.25 and 2.10 ± 0.13 fold increase, respectively. The determination of free and total VEGF demonstrated that the ratio between the two values, evaluated immediately before the 2^(nd) and the 5^(th) cycle of therapy, decreased from 26.65% ± 1.33% to 15.50% ± 3.47% in responsive patients and from 53.41% ± 4.75 to 34.95% ± 2.88% in those with stable disease. Conversely, in those with progression of disease, the ratio showed the opposite behavior coming up from 25.99% ± 5.23% to 51.71% ± 5.28%. The Ang-2 levels did not show any relationship. CONCLUSION: Our data show that the ratio of not BV-bound VEGF to total VEGF serum and BV plasma concentrations for predicting the response to BV plus oxaliplatin-based chemotherapy could be a promising biomarker of response to BV. | Amalia Azzariti Letizia Porcelli Oronzo Brunetti Marzia Del Re Vito Longo Patrizia Nardulli Michele Signorile Jian-Ming Xu Angela Calabrese Anna Elisa Quatrale Evaristo Maiello Vito Lorusso Nicola Silvestris | 2016 | World Journal of Gastroenterology2016，22，27： | 4 |
| 2 | Target Therapies in Pancreatic Carcinoma显示文摘 | Nicola Silvestris Antonio Gnoni Anna Elisabetta Brunetti Leonardo Vincenti Daniele Santini Giuseppe Tonini Francesca Merchionne Evaristo Maiello Vito Lorusso Patrizia Nardulli Amalia Azzariti Michele Reni | 2014 | Current Medicinal Chemistry2014，，8： | 2 |
| 3 | Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity显示文摘 | Letizia Porcelli Anna E. Quatrale Paola Mantuano Maria G. Leo Nicola Silvestris Jean F. Rolland Enza Carioggia Marco Lioce Angelo Paradiso Amalia Azzariti | 2013 | Molecular Oncology2013，，3： | 2 |
| 4 | The effect of gefitinib ( Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines 显示文摘 | Xu JM Azzariti A Colucci G | 2003 | Cancer Chemother Pharmacol2003，52，6： | 1 |
| 5 | Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients:from biological principles to clinical guidelines显示文摘 | Silvestris N Del Re M Azzariti A | | 0，，2： | 1 |
| 6 | Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells显示文摘 | Sebastian S Azzariti A Accardi R | 2008 | Int J Mol Med2008，21，6： | 1 |
| 7 | Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer显示文摘 | Azzariti A Bocci G Porcelli L | 2011 | Br J Cancer2011，104，5： | 1 |
| 8 | Extracellular ADP Prevents Neuronal Apoptosis via Activation of Cell Antioxidant Enzymes and Protection of Mitochondrial ANT-1 显示文摘 | Bobba A Amadoro G Azzariti A | 2014 | Biochim Biophys Acta2014，1837，8： | 1 |
| 9 | Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients:from biologi-cal principles to clinical guidelines显示文摘 | Silvestris N Del Re M Azzariti A | 2012 | Expert Opin Ther Targets2012，162，： | 1 |
| 10 | ZD6474 in- hibits proliferalion and invasion of human hcpatocellular carcino- ma cells显示文摘 | GIANNELLI G AZZARITI A SGARRA C | 2006 | Biochem Pharmacol2006，71，4： | 1 |
| 11 | The effect of gefitinib (Iressa,zd1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines显示文摘 | Xu JM Azzariti A Colucci G | 2003 | Cancer Chemother Pharmacol2003，52，6： | 1 |
| 12 | Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity显示文摘 | Letizia Porcelli Anna E. Quatrale Paola Mantuano Maria G. Leo Nicola Silvestris Jean F. Rolland Enza Carioggia Marco Lioce Angelo Paradiso Amalia Azzariti | 2012 | Molecular Oncology2012，，： | 1 |
| 13 | Characterization of sequence-dependent synergy between ZD1839 ('Iressa') and oxaliplatin显示文摘 | Xu JM Azzariti A Severino M | 2003 | Biochem Pharmacol2003，66，4： | 1 |
| 14 | EGFR and VEGFR as potential target for biological therapies in HCC cells显示文摘 | Gianluigi Giannelli Concetta Sgarra Letizia Porcelli Amalia Azzariti Salvatore Antonaci Angelo Paradiso | 2007 | Cancer Letters2007，，2： | 1 |
| 15 | Synergic antiproliferarive and antiangiogenic effects of EGFR and roTor inhibitors on pancreatic cancer cells显示文摘 | Azzariti A Porcelli L Gatti G | 2008 | Biochem Pharmacol2008，75，5： | 1 |
| 16 | kaminin-5 offsets the efficacy of Gefitinib ('Iressa') in hepatocellular carcinoma cells 显示文摘 | Giannelli G Azzariti A Fransvea E | 2004 | Br J Cancer2004，91，11： | 1 |
| 17 | The effect of gefitinib(Iressa,ZD1839) in combination with oxaliplatin is shedule-dependent in colon cancer cell lines显示文摘 | Xu JM Azzariti A Colucci G | 2003 | Cancer Chemother Pharmacol2003，52，6： | 1 |
| 18 | Aurora B kinase inhibitor AZD1152:determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer显示文摘 | Azzariti A Bocci G Porcelli L | | 0，，： | 1 |
| 19 | Co‐expression of CD133+/CD44+ in human colon cancer and liver metastasis显示文摘 | Antonia Bellizzi Sinto Sebastian Pasquale Ceglia Matteo Centonze Rosa Divella Elvira Foglia Manzillo Amalia Azzariti Nicola Silvestris Severino Montemurro Cosimo Caliandro Raffaele De Luca Giuseppe Cicero Sergio Rizzo Antonio Russo Michele Quaranta Giovan | 2012 | J. Cell. Physiol2012，，2： | 1 |
| 20 | Characterization of sequence- dependent synergy between ZD1839 (' Iressa') and oxaliplatin显示文摘 | Xu JM Azzariti A Severino M | 2003 | Biochem Pharmacol2003，66，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员